REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
1.720 USD   +4.24%
08/11REGULUS : Q2 Earnings Snapshot
AQ
08/11TRANSCRIPT : Regulus Therapeutics Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11REGULUS THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

REGULUS THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)

06/27/2022 | 04:08pm EDT

Item 3.03 Material Modification to Rights of Security Holders.

(a)

On June 24, 2022, Regulus Therapeutics Inc. (the "Company") filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1:10 and decrease the authorized number of shares of the Company's common stock from 400,000,000 shares to 300,000,000 shares (the "Charter Amendment"). The Charter Amendment was authorized by the stockholders of the Company at the Company's 2022 Annual Meeting of Stockholders held on June 9, 2022.

Pursuant to the Charter Amendment, effective at 5:00 p.m. Eastern Time on June 28, 2022 (the "Effective Time"), every ten shares of the Company's issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. As a result of the reverse stock split, proportionate adjustments will be made to the per share conversion ratio and/or the number of shares issuable upon the conversion of the Company's preferred stock outstanding at the Effective Time, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon conversion of the preferred stock. Additionally, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options, restricted stock units and warrants outstanding at the Effective Time, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's 2019 Equity Incentive Plan, 2021 Inducement Plan and 2022 Employee Stock Purchase Plan immediately prior to the Effective Time will be reduced proportionately.

No fractional shares will be issued as a result of the reverse stock split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof. The reverse stock split will affect all stockholders proportionately and will not affect any stockholder's percentage ownership of the Company's common stock (except to the extent that the reverse stock split results in any stockholder owning only a fractional share).

The Company's common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on June 29, 2022. The new CUSIP number for the Company's common stock following the reverse stock split will be 75915K 309.

A copy of the Charter Amendment is filed with this report as Exhibit 3.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
  No.       Exhibit Title or Description

3.1           Certificate of Amendment of the Amended and Restated Certificate of
            Incorporation of Regulus Therapeutics Inc.

104         Cover Page Interactive Data File (the cover page XBRL tags are
            embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about REGULUS THERAPEUTICS INC.
08/11REGULUS : Q2 Earnings Snapshot
AQ
08/11TRANSCRIPT : Regulus Therapeutics Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11REGULUS THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
08/11REGULUS THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Recent Updates - ..
PU
08/11Earnings Flash (RGLS) REGULUS THERAPEUTICS Posts Q2 Loss $-0.50
MT
08/11Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
PR
08/11Regulus Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast..
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations